EUVIMEDEUVIMED entdecken
Crossref

Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma

Ryouta Taomoto, Mikiko Aoki, Toshiyuki Enomoto, Tooru Inoue, Kazuki Nabeshima, Makoto Hamasaki, Hiroshi Abe

Anticancer Research · 2025

DOI: 10.21873/anticanres.17705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Ryouta Taomoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fukuoka University of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Central Nervous System Neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Lymphoma, Large B-Cell, Diffuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Differentiation Factor 88Central Nervous System NeoplasmsCyclin-Dependent Kinase Inhibitor p16Lymphoma, Large B-Cell, DiffuseHumansMaleFemaleMiddle AgedAgedAdultMutationPrognosisAged, 80 and over

Stichwörter der Autor:innen

BTK inhibitorsCDK4/6 inhibitorsCDKN2AMYD88L265PPrimary central nervous system lymphoma

Substanzen

Myeloid Differentiation Factor 88MYD88 protein, humanCyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Fukuoka University of Medicine, Fukuoka, Japan.
  • Department of Pathology, Fukuoka University of Medicine, Fukuoka, Japan.
  • Department of Pathology, Fukuoka University of Medicine, Fukuoka, Japan; mikikoss@fukuoka-u.ac.jp.
  • Department of Neurosurgery, Hakujuji Hospital, Fukuoka, Japan.
  • Department of Pathology, Fukuoka Tokushukai Hospital, Fukuoka, Japan.

Zitieren

APA

Taomoto, R., Aoki, M., Enomoto, T., Inoue, T., Nabeshima, K., Hamasaki, M., & Abe, H. (2025). Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma. Anticancer Research. https://doi.org/10.21873/anticanres.17705

Vancouver

Taomoto R, Aoki M, Enomoto T, Inoue T, Nabeshima K, Hamasaki M, et al. Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma. Anticancer Research. 2025. doi:10.21873/anticanres.17705

BibTeX
@article{Taomoto2025,
  author = {Taomoto, Ryouta and Aoki, Mikiko and Enomoto, Toshiyuki and Inoue, Tooru and Nabeshima, Kazuki and Hamasaki, Makoto and Abe, Hiroshi},
  title = {Molecular Characterization and Therapeutic Implications of MYD88 and CDKN2A in Primary CNS Lymphoma},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17705}
}
Kostenlos starten →